147 related articles for article (PubMed ID: 8027367)
1. Immunohistochemical analysis of CDw52 antigen expression in non-Hodgkin's lymphomas.
Salisbury JR; Rapson NT; Codd JD; Rogers MV; Nethersell AB
J Clin Pathol; 1994 Apr; 47(4):313-7. PubMed ID: 8027367
[TBL] [Abstract][Full Text] [Related]
2. CD30 distribution. Immunohistochemical study on formaldehyde-fixed, paraffin-embedded Hodgkin's and non-Hodgkin's lymphomas.
Miettinen M
Arch Pathol Lab Med; 1992 Nov; 116(11):1197-201. PubMed ID: 1332642
[TBL] [Abstract][Full Text] [Related]
3. CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma.
Lundin J; Osterborg A; Brittinger G; Crowther D; Dombret H; Engert A; Epenetos A; Gisselbrecht C; Huhn D; Jaeger U; Thomas J; Marcus R; Nissen N; Poynton C; Rankin E; Stahel R; Uppenkamp M; Willemze R; Mellstedt H
J Clin Oncol; 1998 Oct; 16(10):3257-63. PubMed ID: 9779699
[TBL] [Abstract][Full Text] [Related]
4. Immunoperoxidase staining of non-Hodgkin's lymphomas for T-cell lineage associated antigens in paraffin sections. Comparison of the performance characteristics of four commercially available antibody preparations.
Kurtin PJ; Roche PC
Am J Surg Pathol; 1993 Sep; 17(9):898-904. PubMed ID: 8352374
[TBL] [Abstract][Full Text] [Related]
5. Methods in pathology. Identification of T-cell lymphomas in paraffin-embedded tissues using polyclonal anti-CD3 antibody: comparison with frozen section immunophenotyping and genotypic analysis.
Anderson C; Rezuke WN; Kosciol CM; Pastuszak WT; Cartun RW
Mod Pathol; 1991 May; 4(3):358-62. PubMed ID: 1829834
[TBL] [Abstract][Full Text] [Related]
6. A phase II multicenter study of CAMPATH-1H antibody in previously treated patients with nonbulky non-Hodgkin's lymphoma.
Khorana A; Bunn P; McLaughlin P; Vose J; Stewart C; Czuczman MS
Leuk Lymphoma; 2001 Mar; 41(1-2):77-87. PubMed ID: 11342359
[TBL] [Abstract][Full Text] [Related]
7. Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H).
Rodig SJ; Abramson JS; Pinkus GS; Treon SP; Dorfman DM; Dong HY; Shipp MA; Kutok JL
Clin Cancer Res; 2006 Dec; 12(23):7174-9. PubMed ID: 17145843
[TBL] [Abstract][Full Text] [Related]
8. p53, c-myc p62 and proliferating cell nuclear antigen (PCNA) expression in non-Hodgkin's lymphomas.
Korkolopoulou P; Oates J; Kittas C; Crocker J
J Clin Pathol; 1994 Jan; 47(1):9-14. PubMed ID: 7907610
[TBL] [Abstract][Full Text] [Related]
9. Immunophenotypic analysis of extranodal non-Hodgkin's lymphomas in the oral cavity.
Takahashi H; Fujita S; Okabe H; Tsuda N; Tezuka F
Pathol Res Pract; 1993 Apr; 189(3):300-11. PubMed ID: 8332573
[TBL] [Abstract][Full Text] [Related]
10. Paraffin-resistant antigens detectable by antibodies L26 and polyclonal CD3 predict the B- or T-cell lineage of 95% of diffuse aggressive non-Hodgkin's lymphomas.
Chadburn A; Knowles DM
Am J Clin Pathol; 1994 Sep; 102(3):284-91. PubMed ID: 8085550
[TBL] [Abstract][Full Text] [Related]
11. BER-H2: a new anti-Ki-1 (CD30) monoclonal antibody directed at a formol-resistant epitope.
Schwarting R; Gerdes J; Dürkop H; Falini B; Pileri S; Stein H
Blood; 1989 Oct; 74(5):1678-89. PubMed ID: 2477085
[TBL] [Abstract][Full Text] [Related]
12. Bauhinia purpurea--a new paraffin section marker for Reed-Sternberg cells of Hodgkin's disease. A comparison with Leu-M1 (CD15), LN2 (CD74), peanut agglutinin, and Ber-H2 (CD30).
Sarker AB; Akagi T; Jeon HJ; Miyake K; Murakami I; Yoshino T; Takahashi K; Nose S
Am J Pathol; 1992 Jul; 141(1):19-23. PubMed ID: 1352944
[TBL] [Abstract][Full Text] [Related]
13. Monoclonal antibody L26: an antibody that is reactive with normal and neoplastic B lymphocytes in routinely fixed and paraffin wax embedded tissues.
Norton AJ; Isaacson PG
J Clin Pathol; 1987 Dec; 40(12):1405-12. PubMed ID: 3323247
[TBL] [Abstract][Full Text] [Related]
14. Cross-linking of the CAMPATH-1 antigen (CD52) mediates growth inhibition in human B- and T-lymphoma cell lines, and subsequent emergence of CD52-deficient cells.
Rowan W; Tite J; Topley P; Brett SJ
Immunology; 1998 Nov; 95(3):427-36. PubMed ID: 9824507
[TBL] [Abstract][Full Text] [Related]
15. CAMPATH-1 monoclonal antibody therapy in severe refractory autoimmune thrombocytopenic purpura.
Lim SH; Hale G; Marcus RE; Waldmann H; Baglin TP
Br J Haematol; 1993 Jul; 84(3):542-4. PubMed ID: 8217808
[TBL] [Abstract][Full Text] [Related]
16. MIB-1, Ki67, and PCNA scores and DNA flow cytometry in intermediate grade malignant lymphomas.
Pich A; Ponti R; Valente G; Chiusa L; Geuna M; Novero D; Palestro G
J Clin Pathol; 1994 Jan; 47(1):18-22. PubMed ID: 7907607
[TBL] [Abstract][Full Text] [Related]
17. CD40 ligand is constitutively expressed in a subset of T cell lymphomas and on the microenvironmental reactive T cells of follicular lymphomas and Hodgkin's disease.
Carbone A; Gloghini A; Gruss HJ; Pinto A
Am J Pathol; 1995 Oct; 147(4):912-22. PubMed ID: 7573367
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical staining of non-Hodgkin's lymphoma with monoclonal antibodies specific for the leucocyte common antigen.
Salter DM; Krajewski AS; Dewar AE
J Pathol; 1985 Aug; 146(4):345-53. PubMed ID: 2411901
[TBL] [Abstract][Full Text] [Related]
19. In vivo expression of the CTLA4 inhibitory receptor in malignant and reactive cells from human lymphomas.
Xerri L; Devilard E; Hassoun J; Olive D; Birg F
J Pathol; 1997 Oct; 183(2):182-7. PubMed ID: 9390031
[TBL] [Abstract][Full Text] [Related]
20. Immunologic markers in non-Hodgkin's lymphoma.
Freedman AS; Nadler LM
Hematol Oncol Clin North Am; 1991 Oct; 5(5):871-89. PubMed ID: 1938759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
